Nicholas Hornstein

Nicholas Hornstein: More ctDNA data than you can shake a stick at GI25

Nicholas Hornstein, Assistant Professor of Medical Oncology at Northwell Health, shared a post on X:

“More ctDNA data than you can shake a stick at GI25.

Early conversion of ctDNA status is a good predictor of patients appropriate for watch and wait in rectal cancer (not just 1, but 2 studies).

α-CORRECT with a brutal sensitivity of only 48% in stage III CRC.

ctDNA in BTC:

Correlation of mid-chemoradiation ctDNA results and clinical complete response to total neoadjuvant therapy (TNT) for locally advanced rectal adenocarcinoma

Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II NEO trial (CCTG CO.28)

Circulating tumor DNA as a marker of recurrence risk in stage III colorectal cancer: The α-CORRECT study

Utilization of circulating tumor DNA (ctDNA) testing in biliary tract cancers“

More posts featuring Nicholas Hornstein.

Biliary tract cancers cancer ctDNA II NEO trial Nicholas Hornstein OncoDaily Oncology rectal cancer The α-CORRECT study TNT tumour